Multiple sclerosis (MS) affects over 400,000 people in the United States and up to 2.5 million in the world. Each week over 200 people are diagnosed with MS and approximately twice as many women are affected by the disease than men. The treatment landscape for MS has changed significantly, not only over the past 20 years, but even in just the past 5 years with the availability of the first oral agent and a multitude of other approvals for MS treatments. There are currently over a dozen U.S. Food and Drug Administration (FDA)-approved disease-modifying agents available for MS patients, with dozens more options for the management of relapses and symptoms associated with the disease.

Family physicians and other healthcare professionals in primary care settings are on the first line to recognize motor, sensory, and cognitive deficits that may help establish a diagnosis of MS. While referral to a neurologist is often made, patients with chronic illnesses such as MS often return to the primary care setting for management. Family clinicians are in a position to help identify and manage relapses, symptoms and treatment-related side effects that all can affect the course of the disease.

Please participate in this online CME/CNE activity which provides a complete review of MS from diagnosis, to treatment, and ongoing management. The activity also includes a discussion of the role that family clinicians and other healthcare professionals in the primary care setting play in the comprehensive care for patients with the disease.

Faculty

thomas_kintanar

Thomas A. Kintanar, MD, FAAFP, DABFM
Lutheran Medical Group
Clinical Associate Professor of Medicine
Indiana University School of Medicine
Fort Wayne, Indiana

sagrella

Stephanie Agrella, MSN, RN, APRN, ANP-BC, MSCN
Director of Clinical Services
Multiple Sclerosis Clinic of Central Texas
Central Texas Neurology Consultants
Round Rock, Texas

CME/CNE Information

Activity Release Date: December 30, 2016
Activity Expiration Date: December 30, 2017
Estimated Time to Complete Activity: 1 hour 15 minutes
Media: Internet

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Review the signs and symptoms of early stages of MS
  • Identify conditions that mimic MS and strategies for facilitating a differential diagnosis
  • Discuss current diagnostic approaches for MS
  • Review current and emerging disease modifying therapies for the treatment of MS
  • Discuss what defines a relapse in MS and appropriate pharmacologic and non-pharmacologic management strategies
  • Review best practices for the coordination of care and collaborative management of MS patients with specialty clinicians

Target Audience
This activity is intended for primary care physicians, nurse practitioners, physician assistants, and all other clinicians with an interest in the care of the patient with multiple sclerosis.

Accreditation and Credit Statements
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Consortium of Multiple Sclerosis Centers (CMSC), Nurse Practitioner Alternatives (NPA), and Catamount Medical Education. CMSC is accredited by the ACCME to provide continuing medical education for physicians.

CMSC designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Alternatives is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. NPA designates this enduring activity for a maximum of 1.25 continuing nursing education credits, with 0.75 pharmacology credits.

This Enduring Material activity, Multiple Sclerosis in the Primary Care Setting: The Role of the Family Practitioner in Improved Diagnosis and Coordination of Care, has been reviewed and is acceptable for up to 1.25 Prescribed credit(s) by the American Academy of Family Physicians. AAFP certification begins 12/30/2016. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Support Acknowledgment
This activity is supported by educational grants from AbbVie, Bayer Pharmaceuticals and Novartis Pharmaceuticals Corporation.

Instructions for Participation and Credit
There are no fees for participating and receiving credit for this activity. During the period that the activity is available for credit, participants must 1) read the CME/CNE information; 2) view the entire video; and 3) complete the post-test and the evaluation form.

A score of at least 3 out of 5 questions correct must be achieved on the post-test to successfully complete the activity. If you do not receive a passing score, you will receive a message notifying you that you did not pass the post-test. You may retake the post-test until successful. Following the post-test and evaluation form your certificate will be made available immediately. Click on the button labeled “Submit Answers and Get Certificate” in order to have your CME/CNE certificate emailed to you for your records.

Technical Requirements
This activity is best viewed using Internet Explorer 10.0 or higher, Google Chrome 49.0 or higher or Firefox 44.0 or higher. For interactive content, a broadband connection is required. For all CME/CNE activities featuring audio you must have a sound card and speakers.

Our activities may require JavaScript to be enabled on your computer.

Faculty and Activity Staff Disclosures
It is the policy of CMSC, NPA, and Catamount Medical Education to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. All faculty, activity planners, content reviewers, and staff participating in this activity have disclosed to the participants any significant financial interest or other relationship with manufacturer(s) of any commercial product(s)/device(s) and/or provider(s) of commercial services included in this educational activity. The intent of this disclosure is not to prevent a person with a relevant financial or other relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. CMSC, NPA, and Catamount Medical Education have identified and resolved any and all conflicts of interest prior to the release of this activity.

The following faculty have indicated they have relationships with industry to disclose relative to the content of this CE activity:

Thomas A. Kintanar, MD, FAAFP, DABFM
Has disclosed no relevant financial relationships.

Stephanie Agrella, MSN, RN, APRN, ANP-BC, MSCN
Consulting fees: Biogen, Sanofi Genzyme
Speakers Bureau: Acorda, Sanofi Genzyme, Serono, Teva

June Halper, MSN, APN-C, MSCN, FAAN, has disclosed no relevant financial relationships.
All other planners, reviewers, staff, or other members of the Continuing Professional Education Committee at the Consortium of Multiple Sclerosis Centers who control content have disclosed no relevant financial relationships.

Laurie Scudder, DNP, NP, has served as Nurse Planner and Reviewer for this activity. She has disclosed no relevant financial relationships.
All other planners, reviewers, and staff at Nurse Practitioner Alternatives who control content have disclosed no relevant financial relationships.

The planners, reviewers, editors, staff, CME committee, or other members at Catamount Medical Education who control content have disclosed no relevant financial relationships.

Disclosure of Unapproved Uses
CMSC, NPA, and Catamount Medical Education require CE faculty (speakers) to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

Privacy Policy
Catamount Medical Education, LLC, respects your privacy. All personal information that is provided to Catamount Medical Education, LLC, is protected and will not be sold to a third party for commercial purposes. All personally identifiable information contained in the Catamount Medical Education, LLC, registration databases is treated as confidential and will be used only for the purposes stated in this policy, except where required by law. Catamount Medical Education, LLC, maintains user databases that contain mailing and user profile information as well as a record of the CME activities viewed and the post-test and evaluation results for CME/CNE credit. This information is provided to activity collaborators for the purposes of CME/CNE recordkeeping. By participating in this activity, you agree that Catamount Medical Education, LLC, has full permission to provide this information

For each visitor to this Web site, our Web server automatically recognizes information such as the visitor’s IP address. Catamount Medical Education, LLC, safeguards against the loss, misuse or alteration of information that we have collected in this activity.

Contact Information
If you have questions about this CME/CNE activity, please contact Catamount Medical Education, LLC, at info@catmeded.com or at 860-661-4164.

 

view-activity-now